Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GHASSAN E HADI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1558497891
CMS profile
70065
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$58.25

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $58.25 3

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GHASSAN E HADI

NPI 1558497891 · CMS profile ID 70065

Allopathic & Osteopathic Physicians / Internal Medicine

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558497891?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558497891?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558497891?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558497891?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $58.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.8312/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960018237 CMS
Amgen Inc. $20.8408/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939943619 CMS
Merck Sharp & Dohme LLC $19.5802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944489343 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $263.01 5
PY2020 $24.75 1
PY2021 $62.66 3
PY2022 $58.25 3
PY2023 $50.93 3
PY2024 $113.96 5
PY2025 $389.94 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,708.88 2
PY2024 Principal investigator $420,960.28 70
PY2023 Principal investigator $204,323.13 66
PY2022 Recipient $16,223.02 2
PY2022 Principal investigator $153,397.33 18
PY2021 Principal investigator $215,215.05 24
PY2020 Principal investigator $212,670.33 84
PY2019 Principal investigator $457,066.36 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $308.00 12/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 12/04/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 12/04/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 12/04/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 12/04/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,436.00 12/04/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137691
Principal investigator 1 Chiesi USA, Inc. $2,739.00 12/01/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051618407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038519
Principal investigator 1 Chiesi USA, Inc. $8,436.00 11/06/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038513
Principal investigator 1 Chiesi USA, Inc. $9,696.00 10/02/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051610551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,093.00 09/13/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,462.00 09/13/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997137483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038397
Principal investigator 1 Chiesi USA, Inc. $42,454.00 08/31/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051605659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038391
Principal investigator 1 Bausch Health US, LLC $7,517.19 07/19/2023 Non-covered Recipient Entity
Ghassan Hadi
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055194949
Principal investigator 1 VIVUS LLC $9,938.00 07/07/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038295
Principal investigator 1 Chiesi USA, Inc. $5,496.00 06/01/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038289
Principal investigator 1 Bausch Health US, LLC $16,486.30 05/26/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055196497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,531.00 05/12/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997165093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,986.00 05/12/2023 Non-covered Recipient Entity
National Institute of Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997165095
Principal investigator 1 VIVUS LLC $33,786.00 05/05/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038283
Principal investigator 1 Bausch Health US, LLC $10,580.20 04/27/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055196499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 02/20/2023 Non-covered Recipient Entity
National Institute of Clinical Research, Upland
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997038165
Principal investigator 1 Bausch Health US, LLC $13,328.52 02/10/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055196493
Principal investigator 1 Bausch Health US, LLC $5,623.02 02/08/2023 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1055196495